Biogen Inc. will ask U.S. drug regulators to approve the company’s experimental Alzheimer’s therapy, reviving the nearly abandoned treatment, after a new analysis of data from two failed clinical trials showed promising results.
US pharmaceuticals company Biogen and its Japanese partner Eisai have announced they will discontinue a global Phase 3 trial for a promising Alzheimer’s disease treatment, aducanumab.
Sian Gregory, from our Will to Remember team, has a background with years of research into stem cells. Here Sian reports on some of the latest dementia research involving them.
Sian Gregory, from our Will to Remember team, has a background with years of research into stem cells. Here Sian reports on some of the latest dementia research involving them.
...
New research, published in the Nature journal today, suggests there may be a relationship between the exercise-induced protein hormone irisin and the progression of Alzheimer's disease.
According to a new study, Yale University researchers have identified a drinkable cocktail of molecules that interferes with a first step of Alzheimer’s disease.
New research shows that a study of the immunotherapy treatment Crenezumab has found it can reduce levels of the protein amyloid, associated with dementia.
New research into the cognitive effects of hormone replacement therapy has been presented at Alzheimer’s Association International Conference (AAIC) in Chicago.
Dementia cannot be cured yet, but there are treatments and support to help someone live well with the condition. Here, we look at different types of treatment and services which can provide support.
Dementia Support Line